J&J sues US Dept. of Health and Human Services and Centers for Medicare and Medicaid Services over the Inflation Reduction Act; J&J claims the Act threatens the pharmaceutical industry, patient access to medicine and may decrease healthcare quality

Sample article from our Consumer Wellness

July 18, 2023 (press release) –

July 18, 2023 – Johnson & Johnson and its Janssen pharmaceutical companies have delivered transformative medicines to patients for more than 130 years. Our ability to deliver these breakthroughs is possible because of a robust research and development ecosystem in which we have invested nearly $65.7 billion since 2016 to prevent, treat, and potentially cure a wide range of devastating diseases.

Today, we filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services to challenge the innovation-damaging drug pricing provisions of the Inflation Reduction Act (IRA). The IRA breaks the agreement at the heart of the patent and regulatory laws: when companies invest and succeed at developing innovative new treatments, they are awarded time-limited and constitutionally protected rights in their innovation.

With the implementation of the IRA, the government is forcing Janssen to provide its innovative, patented medicines on pricing terms that by law must be significantly below market prices. This would upend the current self-sustaining cycle of pharmaceutical innovation that provides patients with access to pioneering treatments, and directly impacts the creation of generic medicines that account for 90% of prescriptions filled in the U.S. If manufacturers do not “agree” to the government-dictated terms of the IRA, they face massive penalties up to 1900% of a selected drug’s daily sales or are forced to withdraw all of their products from both Medicare and Medicaid—potentially depriving nearly 40% of U.S. patients of needed medicines.

We believe that the IRA’s pricing provisions will constrain medical innovation, limit patient access and choice, and negatively impact the overall quality of patient care. We have a responsibility to challenge the current version of the law to protect our ability to continue developing transformative medicines for patients now and in the future.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order consumer wellness coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.